NL-OMON47484已完成不适用
Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy (ADMIRE) for head and neck cancer by twice re-imaging, re-delineation and re-planning during the course of radiotherapy - ADMIRE
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 20 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Histologic biopsy confirmed squamous cell carcinoma of the oral cavity, HPV-negative oropharynx, hypopharynx or larynx
- •Scheduled for radiotherapy or radiotherapy with cisplatin or cetuximab
排除标准
- •Other neoplasms with metastases in the previous 3 years
研究者
相似试验
招募中
3 期
Image-guided focal dose escalation in patients with primary prostate cancer treated with primary external beam hypofractionated radiation therapy (HypoFocal) – a prospective, multicenter, randomized phase III study.Prostate CancerDRKS00022915niversitätsklinikum Freiburg374
招募中
不适用
Functional imaging-guided radiotherapy dose escalation in rectal adenocarcinoma: a feasibility studyRectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)ACTRN12620000757910Dr Myo Min30
进行中（未招募）
不适用
An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine - H2255Acute gout (patients who are refractory or contraindicated to NSAIDs and/or colchicine)MedDRA version: 9.1Level: LLTClassification code 10018628Term: Gout acuteEUCTR2008-004666-61-GBovartis Pharma Services AG200
进行中（未招募）
不适用
An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicine - H2255EUCTR2008-004666-61-FIovartis Pharma Services AG200
进行中（未招募）
不适用
An adaptive dose-ranging, multi-center, single-blind, double-dummy, active-controlled trial to determine the target dose of canakinumab (ACZ885) in the treatment of acute flares in gout patients who are refractory or contraindicated to NSAIDs and/or colchicineEUCTR2008-004666-61-FRovartis Pharma Services AG200